2005
DOI: 10.4161/hv.1.3.1851
|View full text |Cite
|
Sign up to set email alerts
|

Towards an Epitope-Based Human Vaccine for Influenza

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

1
18
0
1

Year Published

2008
2008
2019
2019

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 38 publications
(20 citation statements)
references
References 71 publications
1
18
0
1
Order By: Relevance
“…For example, the flagellin protein of Salmonella can be used as a carrier protein linked to multiple copies of any foreign epitope. However, this approach was used for presentation of small peptides (4,5). Here we present data that support our hypothesis that one bacterial OMP can act as a carrier for a different OMP by providing multiple T-cell epitopes and expanding the repertoire of T-cell epitope presentation on the MHC class II molecules.…”
Section: Vol 76 2008supporting
confidence: 74%
“…For example, the flagellin protein of Salmonella can be used as a carrier protein linked to multiple copies of any foreign epitope. However, this approach was used for presentation of small peptides (4,5). Here we present data that support our hypothesis that one bacterial OMP can act as a carrier for a different OMP by providing multiple T-cell epitopes and expanding the repertoire of T-cell epitope presentation on the MHC class II molecules.…”
Section: Vol 76 2008supporting
confidence: 74%
“…Thus, epitopes may be classified as T- or B-cell epitopes (13,14). With the development of bioinformatic technology, epitope vaccines (15) have become increasingly important in immune prevention. Superior to traditional vaccines, vaccines based on epitopes are currently used as protective measures against infectious diseases.…”
Section: Introductionmentioning
confidence: 99%
“…[2][3][4] Transgenic bacteria expressing modified flagella incorporating antigens have been described as suitable antigen carriers and adjuvants for the development of vaccines for infectious diseases. 5,6 Ben-Yedidia and Arnon 7 suggested the usage of the TLR5 ligand flagellin, the main constituent of bacterial flagella, to strengthen specific immune responses against foreign antigens. Flagellin activates TLR5-expressing cells, potentially leading to an enhanced immune response to foreign epitopes, and improves immune responses after local mucosal application.…”
mentioning
confidence: 99%
“…Flagellin activates TLR5-expressing cells, potentially leading to an enhanced immune response to foreign epitopes, and improves immune responses after local mucosal application. 5 Consequently, flagellin has gained attention as an adjuvant for the prevention of type I allergy. In a murine model of OVA-induced airway hyperreactivity, intranasal coadministration of flagellin mixed with ovalbumin (OVA) resulted in the suppression of airway hyperreactivity, inflammation, and OVA-specific T H 2 cytokine secretion.…”
mentioning
confidence: 99%